$CMPS News

COMPASS Pathways (CMPS) Stock May Trade At A Premium After Positive Phase 3 Results

Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

Compass Pathways Reports Q2 2026 Results: Full Earnings Call Transcript

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

COMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III Progress

Compass Pathways Appoints Kelley Boucher as Chief People Officer

Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

COMPASS Pathways plc (CMPS) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

COMPASS Pathways plc (CMPS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026

COMPASS Pathways (CMPS) Stock May Be Fully Priced On Phase 3 Data

Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026

Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360

Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training

Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training

Compass Pathways to Participate in Investor Conferences the Week of September 14th

Compass Pathways Announces U.S. Healthcare Provider Grant Program Recipients To Create Training For Delivery Of Psychedelic Treatments